MicroRNA 634 (miR-634)

MicroRNA 634 is a small, non-coding RNA that regulates gene expression by binding to complementary sequences in target mRNAs, leading to mRNA degradation or translational inhibition. It is particularly notable for its broad tumor-suppressive roles across multiple cancer types by promoting apoptosis, suppressing cell proliferation, and sensitizing cells to chemotherapeutic agents such as paclitaxel (in nasopharyngeal carcinoma) and temozolomide (in glioma). miR-634 also regulates key cancer-related pathways, such as mTOR and PI3K/Akt, and targets specific proteins including RAB1A, DHX33, HSPA2, and PIK3R1. Expression of microRNA 634 is commonly downregulated in tumors, and low levels correlate with worse prognosis and chemotherapy resistance, making it a candidate biomarker for therapy response and a potential therapeutic target in oncology.

Other names

MIR634hsa-mir-634MIRN634

Drugs may upregulate miR-634 (e.g., via mimics or gene therapy approaches), sensitizing cancer cells to cytotoxic chemotherapy via enhanced apoptosis and inhibition of pro-survival pathways. miR-634 regulates targets such as RAB1A, DHX33, mTOR pathway members, PIK3R1, and HSPA2, leading to growth suppression and increased chemotherapy sensitivity.